PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
Margaret K CallahanPaul B ChapmanPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)